Best practices in patent license negotiations
Article Abstract:
Licenses to intellectual property (IP) are a fundamental part of the pharmaceutical and biotech industry. An outline of license negotiation is described and also the need for well-planned, forward-thinking manner to approach the process so that both the licensees and licensors, especially those with various types of expertise can reap maximum benefits for biotechnological and pharmaceutical inventions and set a base for a solid working relationship in the future is mentioned.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Determining the meaning of claim terms
Article Abstract:
A patent owner should take great care while constructing claims asserted to be infringed in order to establish what the protected invention constitutes. The infringement case fought by Phillips v. AWH signifies the importance of defining a claim in the context of the entire patent rather than relying on outside sources.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Recent Supreme Court decisions and licensing power
Article Abstract:
The decisions of the United States Supreme Court issued on eBay and MedImmune have strongly influenced the licenses and the important decisions to be kept in mind during the license negotiations, thus exclaiming both reassurance and uncertainty into the patent licensing scenario.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2008
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Either/or selection markers for plant transformation. Monitoring and modeling horizontal gene transfer. The fate of transgenes in the human gut
- Abstracts: First steps on a long journey. Getting a clear view
- Abstracts: Resource crisis in Ghana. The answer to technology. Grant Thornton feasts on Robson Rhodes
- Abstracts: Nuclear transfer cloning and the United Nations. Merck's HIV vaccine flop brings vectors under closer scrutiny
- Abstracts: Time to account for our actions. Better pay reporting. Rising to the green challenge